|Classification and external resources|
a radiograph of bronchopulmonary dysplasia
|Patient UK||Bronchopulmonary dysplasia|
Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disorder that is most common among children who were born prematurely. Bronchopulmonary dysplasia results in significant morbidity and mortality. Bronchopulmonary dysplasia is more common in infants with low birth weight and those who received prolonged mechanical ventilation to treat respiratory distress syndrome. BPD was first described in the literature in 1967 and was originally attributed to the effects of oxygen and mechanical ventilation in premature infants with severe respiratory distress syndrome (RDS). The definition of BPD has continued to evolve since then primarily due to changes in the population, such as more survivors at earlier gestational ages, and improved neonatal management including surfactant, antenatal glucocorticoid therapy, and less aggressive mechanical ventilation.
Currently the description of BPD includes the grading of its severity into mild, moderate and severe. This correlates with the infant's maturity, growth and overall severity of illness. The new system offers a better description of underlying pulmonary disease and its severity.
The classic diagnosis of BPD may be assigned at 28 days of life if the following criteria are met:
- Positive pressure ventilation during the first 2 weeks of life for a minimum of 3 days.
- Clinical signs of abnormal respiratory function.
- Requirements for supplemental oxygen for longer than 28 days of age to maintain PaO2 above 50 mm Hg.
- Chest radiograph with diffuse abnormal findings characteristic of BPD.
- Breathing room air at 36 weeks post-menstrual age or discharge (whichever comes first) for babies born before 32 weeks, or
- breathing room air by 56 days postnatal age, or discharge (whichever comes first) for babies born after 32 weeks gestation.
- Need for <30% oxygen at 36 weeks postmenstrual age, or discharge (whichever comes first) for babies born before 32 weeks, or
- need for <30% oxygen to 56 days postnatal age, or discharge (whichever comes first).
- Need for >30% oxygen, with or without positive pressure ventilation or continuous positive pressure at 36 weeks postmenstrual age, or discharge (whichever comes first) for babies born before 32 weeks, or
- need for >30% oxygen with or without positive pressure ventilation or continuous positive pressure at 56 days postnatal age, or discharge (whichever comes first) for babies born after 32 weeks' gestation.
BPD is characterized by inflammation and scarring in the lungs. More specifically, the high pressures of oxygen delivery result in necrotizing bronchiolitis and alveolar septal injury, further compromising oxygenation of blood. Today, with the advent of surfactant therapy and high frequency ventilation and oxygen supplementation, infants with BPD experience much milder injury without necrotizing bronchiolitis or alveolar septal fibrosis. Instead, there are usually uniformly dilated acini with thin alveolar septa and little or no interstitial fibrosis. It develops most commonly in the first 4 weeks after birth.
- crackles, wheezing, & decreased breath sounds;
- increased bronchial secretions;
- frequent lower respiratory infections;
- delayed growth & development;
- cor pulmonale;
- CXR shows with hyperinflation, low diaphragm, atelectasis, cystic changes.
There is evidence to show that steroids given to babies less than 8 days old can prevent bronchopulmonary dysplasia. However, the risks of treatment may outweigh the benefits. It is unclear if starting steroids more than 7 days after birth is harmful or beneficial. It is thus recommended that they only be used in those who cannot be taken off of a ventilator.
The rate of BPD varies among institutions, which may reflect neonatal risk factors, care practices (e.g., target levels for acceptable oxygen saturation), and differences in the clinical definitions of BPD.
- Respiratory care
- Respiratory distress syndrome
- Wilson–Mikity syndrome
- Northway Jr, WH; Rosan, RC; Porter, DY (Feb 16, 1967). "Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.". The New England Journal of Medicine 276 (7): 357–68. doi:10.1056/NEJM196702162760701. PMID 5334613.
- Sahni, R; Ammari, A; Suri, MS; Milisavljevic, V; Ohira-Kist, K; Wung, JT; Polin, RA (Jan 2005). "Is the new definition of bronchopulmonary dysplasia more useful?". Journal of perinatology : official journal of the California Perinatal Association 25 (1): 41–6. doi:10.1038/sj.jp.7211210. PMID 15538399.
- Ehrenkranz, RA; Walsh, MC; Vohr, BR; Jobe, AH; Wright, LL; Fanaroff, AA; Wrage, LA; Poole, K; National Institutes of Child Health and Human Development Neonatal Research, Network (Dec 2005). "Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia". Pediatrics 116 (6): 1353–60. doi:10.1542/peds.2005-0249. PMID 16322158.
- Bureau of Maternal and Child Health, 1989
- Kinsella, JP; Greenough, A; Abman, SH (Apr 29, 2006). "Bronchopulmonary dysplasia". Lancet 367 (9520): 1421–31. doi:10.1016/S0140-6736(06)68615-7. PMID 16650652.
- "Bronchopulmonary Dysplasia". Patient.co.uk. Retrieved 2 February 2014.
- Gaining & Growing. "Bronchopulmonary dysplasia", Gaining & Growing, March 20, 2007. (Retrieved June 12, 2008.)
- Doyle, LW; Ehrenkranz, RA; Halliday, HL (May 13, 2014). "Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.". The Cochrane database of systematic reviews 5: CD001146. PMID 24825456.
- Doyle, LW; Ehrenkranz, RA; Halliday, HL (May 13, 2014). "Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants.". The Cochrane database of systematic reviews 5: CD001145. PMID 24825542.
- Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR et al. (2007). "Trends in neonatal morbidity and mortality for very low birthweight infants". Am J Obstet Gynecol 196 (2): 147.e1–8. doi:10.1016/j.ajog.2006.09.014. PMID 17306659.
- Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M et al. (2000). "Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network". Pediatrics 105 (6): 1194–201. doi:10.1542/peds.105.6.1194. PMID 10835057.
- Ellsbury DL, Acarregui MJ, McGuinness GA, Eastman DL, Klein JM (2004). "Controversy surrounding the use of home oxygen for premature infants with bronchopulmonary dysplasia". J Perinatol 24 (1): 36–40. doi:10.1038/sj.jp.7211012. PMID 14726936.
- Bhandari, A; Bhandari, V (Jan 2007). "Bronchopulmonary dysplasia: an update". Indian journal of pediatrics 74 (1): 73–7. doi:10.1007/s12098-007-0032-z. PMID 17264460.
- Bronchopulmonary Dysplasia on National Institutes of Health